The phase 3 PARADIGM study randomly assigned patients with metastatic colorectal cancer to receive either mFOLFOX6 with panitumumab or with bevacizumab.
However, in the Phase III PARADIGM trial, there was no difference in survival between the two arms when researchers focused only on patients with right-sided tumors.
CHICAGO — The addition of panitumumab vs. bevacizumab to standard doublet chemotherapy significantly extended survival among patients with RAS wild-type and left-sided metastatic colorectal cancer, according to study results.The panitumumab (Vectibix, Amgen) regimen conferred median OS of more than 3 years —— the longest survival ever reported in a first-line, prospective phase
The first trial comparing panitumumab or bevacizumab plus standard chemotherapy has shown that the former significantly improves survival in left-sided Ras wild type metastatic colorectal cancer.